COVID-19 Impact on Global Targeted Drugs for Multiple Myeloma Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Immunomodulator
  • 1.4.3 Proteasome Inhibitors
  • 1.4.4 Histone Deacetylase Inhibitors (HDACI)
  • 1.4.5 Monoclonal Antibody
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Drug Center
  • 1.5.4 Clinic
  • 1.5.5 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for Multiple Myeloma Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Targeted Drugs for Multiple Myeloma Industry
    • 1.6.1.1 Targeted Drugs for Multiple Myeloma Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Targeted Drugs for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Targeted Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Targeted Drugs for Multiple Myeloma Market Perspective (2015-2026)
• 2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Regions
  • 2.2.1 Targeted Drugs for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  • 2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Targeted Drugs for Multiple Myeloma Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Targeted Drugs for Multiple Myeloma Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Market Size
  • 3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2015-2020)
  • 3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
  • 3.2.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2019
• 3.3 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
• 3.4 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
• 3.5 Date of Enter into Targeted Drugs for Multiple Myeloma Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2015-2020)
• 4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

5 Targeted Drugs for Multiple Myeloma Breakdown Data by Application (2015-2026)

• 5.1 Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
• 5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 6.2 Targeted Drugs for Multiple Myeloma Key Players in North America (2019-2020)
• 6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 7.2 Targeted Drugs for Multiple Myeloma Key Players in Europe (2019-2020)
• 7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

8 China

• 8.1 China Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 8.2 Targeted Drugs for Multiple Myeloma Key Players in China (2019-2020)
• 8.3 China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 8.4 China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 9.2 Targeted Drugs for Multiple Myeloma Key Players in Japan (2019-2020)
• 9.3 Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 9.4 Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 10.2 Targeted Drugs for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 10.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

11 India

• 11.1 India Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 11.2 Targeted Drugs for Multiple Myeloma Key Players in India (2019-2020)
• 11.3 India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 11.4 India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
• 12.2 Targeted Drugs for Multiple Myeloma Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
• 12.4 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Celgene
  • 13.1.1 Celgene Company Details
  • 13.1.2 Celgene Business Overview and Its Total Revenue
  • 13.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
  • 13.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020))
  • 13.1.5 Celgene Recent Development
• 13.2 Exova
  • 13.2.1 Exova Company Details
  • 13.2.2 Exova Business Overview and Its Total Revenue
  • 13.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction
  • 13.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.2.5 Exova Recent Development
• 13.3 Natco Pharma
  • 13.3.1 Natco Pharma Company Details
  • 13.3.2 Natco Pharma Business Overview and Its Total Revenue
  • 13.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction
  • 13.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.3.5 Natco Pharma Recent Development
• 13.4 Intas Pharmaceuticals
  • 13.4.1 Intas Pharmaceuticals Company Details
  • 13.4.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
  • 13.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
  • 13.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.4.5 Intas Pharmaceuticals Recent Development
• 13.5 Indiabulls Pharmaceutical
  • 13.5.1 Indiabulls Pharmaceutical Company Details
  • 13.5.2 Indiabulls Pharmaceutical Business Overview and Its Total Revenue
  • 13.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
  • 13.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.5.5 Indiabulls Pharmaceutical Recent Development
• 13.6 Cipla
  • 13.6.1 Cipla Company Details
  • 13.6.2 Cipla Business Overview and Its Total Revenue
  • 13.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction
  • 13.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.6.5 Cipla Recent Development
• 13.7 Glenmark Pharmaceuticals
  • 13.7.1 Glenmark Pharmaceuticals Company Details
  • 13.7.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
  • 13.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
  • 13.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.7.5 Glenmark Pharmaceuticals Recent Development
• 13.8 Dr Reddy's Laboratories
  • 13.8.1 Dr Reddy's Laboratories Company Details
  • 13.8.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue
  • 13.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction
  • 13.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.8.5 Dr Reddy's Laboratories Recent Development
• 13.9 Qilu Pharmaceutical
  • 13.9.1 Qilu Pharmaceutical Company Details
  • 13.9.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
  • 13.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
  • 13.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.9.5 Qilu Pharmaceutical Recent Development
• 13.10 Chia Tai-Tianqing
  • 13.10.1 Chia Tai-Tianqing Company Details
  • 13.10.2 Chia Tai-Tianqing Business Overview and Its Total Revenue
  • 13.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction
  • 13.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 13.10.5 Chia Tai-Tianqing Recent Development
• 13.11 Hanson Pharm
  • 10.11.1 Hanson Pharm Company Details
  • 10.11.2 Hanson Pharm Business Overview and Its Total Revenue
  • 10.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction
  • 10.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.11.5 Hanson Pharm Recent Development
• 13.12 Meidakang Huakang Pharmaceutical
  • 10.12.1 Meidakang Huakang Pharmaceutical Company Details
  • 10.12.2 Meidakang Huakang Pharmaceutical Business Overview and Its Total Revenue
  • 10.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
  • 10.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.12.5 Meidakang Huakang Pharmaceutical Recent Development
• 13.13 Shandong Kongfu Pharmaceutical
  • 10.13.1 Shandong Kongfu Pharmaceutical Company Details
  • 10.13.2 Shandong Kongfu Pharmaceutical Business Overview and Its Total Revenue
  • 10.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
  • 10.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.13.5 Shandong Kongfu Pharmaceutical Recent Development
• 13.14 J&J
  • 10.14.1 J&J Company Details
  • 10.14.2 J&J Business Overview and Its Total Revenue
  • 10.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
  • 10.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.14.5 J&J Recent Development
• 13.15 Takeda
  • 10.15.1 Takeda Company Details
  • 10.15.2 Takeda Business Overview and Its Total Revenue
  • 10.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
  • 10.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.15.5 Takeda Recent Development
• 13.16 Amgen
  • 10.16.1 Amgen Company Details
  • 10.16.2 Amgen Business Overview and Its Total Revenue
  • 10.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
  • 10.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.16.5 Amgen Recent Development
• 13.17 Bristol Myers Squibb
  • 10.17.1 Bristol Myers Squibb Company Details
  • 10.17.2 Bristol Myers Squibb Business Overview and Its Total Revenue
  • 10.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
  • 10.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.17.5 Bristol Myers Squibb Recent Development
• 13.18 Abbvie
  • 10.18.1 Abbvie Company Details
  • 10.18.2 Abbvie Business Overview and Its Total Revenue
  • 10.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
  • 10.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.18.5 Abbvie Recent Development
• 13.19 Seattle Genetics
  • 10.19.1 Seattle Genetics Company Details
  • 10.19.2 Seattle Genetics Business Overview and Its Total Revenue
  • 10.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
  • 10.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.19.5 Seattle Genetics Recent Development
• 13.20 Karyopharm Therapeutics
  • 10.20.1 Karyopharm Therapeutics Company Details
  • 10.20.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
  • 10.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
  • 10.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.20.5 Karyopharm Therapeutics Recent Development
• 13.21 PDL BioPharma
  • 10.21.1 PDL BioPharma Company Details
  • 10.21.2 PDL BioPharma Business Overview and Its Total Revenue
  • 10.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
  • 10.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.21.5 PDL BioPharma Recent Development
• 13.22 Roche
  • 10.22.1 Roche Company Details
  • 10.22.2 Roche Business Overview and Its Total Revenue
  • 10.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
  • 10.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.22.5 Roche Recent Development
• 13.23 Sumitomo
  • 10.23.1 Sumitomo Company Details
  • 10.23.2 Sumitomo Business Overview and Its Total Revenue
  • 10.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
  • 10.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.23.5 Sumitomo Recent Development
• 13.24 Merck
  • 10.24.1 Merck Company Details
  • 10.24.2 Merck Business Overview and Its Total Revenue
  • 10.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction
  • 10.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.24.5 Merck Recent Development
• 13.25 Biogen
  • 10.25.1 Biogen Company Details
  • 10.25.2 Biogen Business Overview and Its Total Revenue
  • 10.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction
  • 10.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.25.5 Biogen Recent Development
• 13.26 Schering-Plough
  • 10.26.1 Schering-Plough Company Details
  • 10.26.2 Schering-Plough Business Overview and Its Total Revenue
  • 10.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction
  • 10.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.26.5 Schering-Plough Recent Development
• 13.27 Glaxo
  • 10.27.1 Glaxo Company Details
  • 10.27.2 Glaxo Business Overview and Its Total Revenue
  • 10.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction
  • 10.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.27.5 Glaxo Recent Development
• 13.28 Chiron
  • 10.28.1 Chiron Company Details
  • 10.28.2 Chiron Business Overview and Its Total Revenue
  • 10.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction
  • 10.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  • 10.28.5 Chiron Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer